Abstract
Acquired inhibitors of factor V are rare causes of clinical bleeding, whose severity ranges from mild to life-threatening. Optimal treatment of patients with factor V inhibitors is uncertain. We report on our successful treatment approach in a patient with spontaneous, life-threatening intracranial bleeding caused by a factor V inhibitor. The patient deteriorated after initial treatment with fresh-frozen plasma and platelet transfusions. He was subsequently treated with a combination of plasma exchange and chemotherapy, which led to complete recovery. Our experience suggests that plasma exchange may be life-saving in cases of severe bleeding caused by factor V inhibitors. The use of plasmapheresis in conjunction with chemotherapy is an efficacious and well-tolerated treatment and should be considered in patients with factor V inhibitors.
Author supplied keywords
Cite
CITATION STYLE
Fu, Y. X., Kaufman, R., Rudolph, A. E., Collum, S. E., & Blinder, M. A. (1996). Multimodality therapy of an acquired factor V inhibitor. American Journal of Hematology, 51(4), 315–318. https://doi.org/10.1002/(SICI)1096-8652(199604)51:4<315::AID-AJH11>3.0.CO;2-D
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.